And even with a large portfolio of candidates in other fields, Eli Lilly could also encounter significant clinical setbacks in these other markets
The FDA is currently reviewing high-dose oral semaglutide, and a decision from the drug administration could make this new option available to patients by late 2025
A meta-analysis of randomized trials in newly diagnosed glioblastoma [abstract]
BPC-157 is often studied for its role in supporting tissue repair and reducing inflammation
Defendants have proposed completing fact discovery by October 2026, expert discovery by year-end, and full briefing on motions by the first quarter of 2027
Their clinical trials (NCT04542161) conclusively demonstrated that ME/CFS patients suffer from a significant, localized deficit of glutathione in the cerebral cortex, directly correlating with the severity of their neuroinflammation and cognitive dysfunction